Previous 10 |
BioXcel's (NASDAQ: BTAI ) investigational drug BXCL501 - a proprietary sublingual film of dexmedetomidine, for the treatment of acute agitation - has been granted Fast Track Designation by the FDA. More news on: BioXcel Therapeutics, Healthcare stocks news, Stocks on the move, Rea...
NEW HAVEN, Conn., Dec. 27, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that the U.S. FDA has granted Fast Track Designation for its investigational drug BXCL501, a proprietary sublingual film of dexmede...
NEW HAVEN, Conn., Dec. 03, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immun...
First-in-human Phase 1b / 2 combination trial of BXCL701 and pembrolizumab (Keytruda®) expected to initiate in 4Q 2018 Efficacy study with objective response rate endpoint to enroll up to 40 patients at multiple clinical sites NEW HAVEN, Conn., Nov. 05, 2018 (GLOBE NEWSWIR...
Conference call scheduled for November 09, 2018 at 8:00 AM ET NEW HAVEN, Conn., Nov. 02, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to...
Data underscores the potential of triple combination of BXCL701, NKTR-214 and an anti-PD1 agent as an anti-cancer therapy NEW HAVEN, Conn., Oct. 31, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical develo...
On track to initiate BXCL501 first-in-human pharmacokinetic (bioavailability) and safety study Data readout expected first half 2019 NEW HAVEN, Conn., Oct. 30, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutic...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
NEW HAVEN, Conn., July 30, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its second quarter 2024 financ...
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...